Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril valsartan vs trichlormethiazide on renal injury markers in type 2 diabetes with diabetic nephropathy
jRCT1011240028Not yet recruiting
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sacubitril + valsartan and Trichlormethiazide in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis and hypertension (HTN) (2 arms). Primary endpoint: Primary: Change in urinary L-FABP and urinary albumin. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
sacubitril + valsartanTrichlormethiazide
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosishypertension (HTN)
Beyond the preview
Go deeper on jRCT1011240028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011240028.